There will be a second straight week with a calendar chalk-full of IPOs.<\/p>\n
Six IPOs were on this week’s schedule as of Friday and another five launched this morning.<\/p>\n
Debuting Wednesday (9\/23)<\/strong><\/span><\/p>\n Bentley Systems, Inc. (BSY) — <\/b>T<\/span>heir mission is to provide innovative software to advance the design, construction, and operations of the world\u2019s infrastructure\u2014sustaining both the global economy and environment, for improved quality of life.<\/p>\n Corsair Gaming, Inc. (CRSR) —<\/b> \u00a0<\/b>They are a leading global provider and innovator of high-performance gear for gamers and content creators.\u00a0\u00a0<\/span><\/p>\n GoodRx Holdings, Inc. (GDRX) — <\/b>\u00a0\u00a0They are building the leading, consumer-focused digital healthcare platform in the United States.\u00a0<\/span><\/p>\n Debuting Thursday (9\/24)<\/strong><\/span><\/p>\n Taysha Gene Therapies, Inc.\u00a0 (TSHA)<\/b> — They are a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations.\u00a0<\/span><\/p>\n Debuting Friday (9\/25)<\/strong><\/span><\/p>\n Graybug Vision, Inc. (GRAY) — <\/b>\u00a0They are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.<\/span><\/p>\n Hygo Energy Transition Ltd. (HYGO) <\/b>— <\/b>\u00a0<\/span>They provide integrated downstream LNG solutions to underserved markets by delivering low cost, environmentally sound energy alternatives to consumers around the world.<\/p>\n Laird Superfood, Inc. (LSF) <\/b>—\u00a0 <\/b>Laird Superfood is an emerging consumer products platform focused on manufacturing and marketing highly differentiated plant-based and functional foods.<\/p>\n Orphazyme A\/S (ORPH) –\u00a0<\/b>They are a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases.\u00a0Note: <\/i><\/b>Their<\/i> ordinary shares are listed on Nasdaq Copenhagen A\/S, or Nasdaq Copenhagen, under the symbol \u201cORPHA.\u201d<\/i><\/span><\/p>\n PMV Pharmaceuticals, Inc (PMVP) —\u00a0<\/b>They are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 is a well-defined tumor suppressor protein known as the \u201cguardian of the genome,\u201d and normal, or wild-type, p53 has the ability to eliminate cancer cells. <\/span><\/p>\n Prelude Therapeutics Incorporated (PRLD) —\u00a0<\/b>They are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.<\/span><\/p>\n